WO2018086243A1 - 氟硼二吡咯衍生物及其制备方法和在医药上的应用 - Google Patents
氟硼二吡咯衍生物及其制备方法和在医药上的应用 Download PDFInfo
- Publication number
- WO2018086243A1 WO2018086243A1 PCT/CN2017/070300 CN2017070300W WO2018086243A1 WO 2018086243 A1 WO2018086243 A1 WO 2018086243A1 CN 2017070300 W CN2017070300 W CN 2017070300W WO 2018086243 A1 WO2018086243 A1 WO 2018086243A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- formula
- group
- boraindacene
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 49
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- -1 Hexafluorophosphate Chemical compound 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 230000002165 photosensitisation Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 125000005626 carbonium group Chemical group 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 claims description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 claims description 2
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 21
- 206010034972 Photosensitivity reaction Diseases 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 8
- 230000036211 photosensitivity Effects 0.000 abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 3
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000002428 photodynamic therapy Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- USARTISFYYMSBD-UHFFFAOYSA-N N1C=CC=C1.N1C=CC=C1.F[B] Chemical class N1C=CC=C1.N1C=CC=C1.F[B] USARTISFYYMSBD-UHFFFAOYSA-N 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960001701 chloroform Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960003569 hematoporphyrin Drugs 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical class [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- JACPFCQFVIAGDN-UHFFFAOYSA-M sipc iv Chemical compound [OH-].[Si+4].CN(C)CCC[Si](C)(C)[O-].C=1C=CC=C(C(N=C2[N-]C(C3=CC=CC=C32)=N2)=N3)C=1C3=CC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 JACPFCQFVIAGDN-UHFFFAOYSA-M 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ULUNQYODBKLBOE-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrole Chemical class C1=CNC(C=2NC=CC=2)=C1 ULUNQYODBKLBOE-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical group N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 0 C*OCCC(C)(C)Oc(cc1)ccc1C(C1=C(C)C(C)=C(CCc(cc2)ccc2OCC(*CCOC(C)(C)OCC**)=O)*1*1(N)N)=C2*1=C(C=Cc(cc1)ccc1OCC(*CCOC(C)(C)OCC**)=O)C(C)=C2C Chemical compound C*OCCC(C)(C)Oc(cc1)ccc1C(C1=C(C)C(C)=C(CCc(cc2)ccc2OCC(*CCOC(C)(C)OCC**)=O)*1*1(N)N)=C2*1=C(C=Cc(cc1)ccc1OCC(*CCOC(C)(C)OCC**)=O)C(C)=C2C 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
Definitions
- the invention belongs to the field of medicine, relates to a fluoroboron dipyrrole derivative, a preparation method thereof and application thereof in medicine, and discloses the use thereof as a photosensitizer for treating cancer.
- Photodynamic Therapy also known as Photoradiation Therapy (PRT) or Photochemotherapy
- PDT Photodynamic Therapy
- PS Photoradiation Therapy
- the photosensitizer is injected into the body by intravenous injection (for the skin, it can also be applied to the affected area).
- the tumor tissue is irradiated with light of a specific wavelength, and the photosensitizer enriched in the tumor tissue is excited by light.
- Photodynamic therapy can also effectively treat non-cancer diseases such as bacterial infections, oral infections, macular degeneration, arteriosclerosis, traumatic infections, and skin diseases.
- Photosensitizers can also be used for photodynamic disinfection, most importantly for sterilization of blood and blood derivatives.
- photodynamic diagnosis using the fluorescent properties of photosensitizers is also an important use of medical photosensitizers.
- the key to photodynamic therapy lies in photosensitizers, and the photodynamic efficacy depends on the pros and cons of photosensitizers. Based on the potential of photodynamic therapy in the treatment of tumors and other diseases, the scientific community generally believes that photodynamic therapy will become an important medical method in the 21st century.
- the main photosensitizer used in clinical practice is Porfimer sodium (Photofin), which has been listed in 28 countries and regions such as the Netherlands, Canada, Japan, the United States, France, Germany, and the United Kingdom. China's research on photodynamic therapy (PDT) started later than the United States, Japan and other countries, but the progress is faster. Since the early 1980s, a lot of work has been done to develop photodynamic therapy.
- Hematoporphyrin Hematoporphyrin
- SFDA State Food and Drug Administration
- hypoxic microenvironment in the solid tissue of the tumor results in a lower pH outside the tumor (about 6.5), while the extracellular pH of the normal tissue is about 7.4.
- the difference in pH between tumor solid tissue and normal tissue provides a new strategy for the design of tumor-targeted drugs.
- the inventors of the present invention have reported in recent years a number of series of pH-sensitive photosensitizing drugs, such as axial amino derivatives replacing silicon phthalocyanine, which affect the photosensitivity by different degrees of ionization of amino groups in different pH environments ( Jiang, X.-J .et.al, Chem.Commun., 2010, 46, 3188-3190); Axial phenyl derivatives replace silicon phthalocyanine, which affects photosensitivity by different degrees of aggregation of phthalocyanine molecules in a pH environment ( Jiang, X.- J. et . al, Chem. Eur. J.
- these compounds and most of the pH-sensitive drugs reported so far are not tumor cell extracellular micro-acid environment-targeting drugs, because the subcellular tissues of tumor cells and normal cells such as mitochondria and lysosomes are acidic, lysozyme
- the pH of the body can be as low as 5.
- These compounds, when taken up by tumor cells and normal cells, can be stimulated by the acid in the subcellular tissue to damage the photosensitizing activity and damage the tumor cells and normal cells.
- the present invention discloses a series of tumor extracellular microacid environments that target photosensitizing drugs.
- a series of structures, synthesis and applications of ketal-linked cholesterol-fluoroboron dipyrrole derivatives are disclosed.
- the fluoroboron dipyrrole derivative introduces a cholesterol group, and the fluoroboron dipyrrole derivative and cholesterol are linked by an acid-sensitive ketal bond.
- cholesterol-fluoroboron dipyrrole Derivatives are difficult to be taken up by cancer cells and normal cells, but in the micro-acid environment outside the tumor solid tissue cells, the ketal bond is hydrolyzed, the cholesterol group is shed, and the fluoroboron dipyrrole hydrolyzed derivative can be taken up by cancer cells. And exhibits extremely high photosensitivity, they are targeted to photo-sensitive drugs in the extracellular micro-acid environment of tumors.
- the present invention provides a compound of the formula (I):
- the hydrolysate of the compound of the formula (I) is a compound of the formula (V) having the same structure and similar structure as the compound reported in the literature ( Jiang, X.-J. et . al, Chem. Eur. J.) . 2016, 22, 8273-8281), these compounds have high uptake rates in tumor cells and exhibit very high photosensitivity at very low concentrations.
- the present invention also provides a process for the preparation of a compound of the formula (I), which comprises:
- the solvent is selected from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, dichloromethane, chloroform and tetrahydrofuran; the reaction is carried out at a temperature of -5 to 80 ° C;
- the basic condition is provided by a reagent selected from the group consisting of pyridine, triethylamine, sodium hydride and 4-N,N-lutidine; the molar ratio of the compound of the formula (II) to cholesterol formyl chloride is 1:0.2-2 ;
- the solvent is selected from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, dichloromethane, chloroform and tetrahydrofuran;
- the catalyst is selected from the group consisting of triethylamine, pyridine, N, N- Lutidine;
- the condensing agent is dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1 -ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride, O-(7-azabenzotriazol-1-yl)-bis(dimethylamino)carbonate Hexafluorophosphate, O-(benzotriazol-1-yl)-bis(dimethylamino)carbonium hexafluorophosphate, O-(benzotriazol-1-y
- the compound can also be purified by methods well known to those skilled in the art, such as by distillation, by silica gel column chromatography or by high performance liquid chromatography (HPLC).
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for the preparation of a photodynamic drug or a photosensitizing drug.
- the present invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for the preparation of a medicament for treating cancer.
- the cancer described therein is selected from the group consisting of lung cancer, gastric cancer, esophageal cancer, breast cancer, bladder cancer, prostate cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, colon cancer, skin cancer, head and neck cancer, Eye tumor, uterine cancer and ovarian cancer, excellent breast cancer.
- the present invention also relates to a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a photodynamic drug or a photosensitizing drug.
- the present invention also relates to a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is useful for treating cancer.
- the cancer described therein is selected from the group consisting of lung cancer, gastric cancer, esophageal cancer, breast cancer, bladder cancer, prostate cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, colon cancer, skin cancer, head and neck cancer, eye tumor, uterine cancer and ovary. Cancer, preferably breast cancer.
- the present invention also relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, and then suitably
- the light source is illuminated.
- the suitable light source may be provided by a conventional light source coupled to a suitable filter or by a laser of a particular wavelength, the source having a wavelength in the range of 550 to 900 nm, preferably 620 to 720 nm.
- the compounds according to the invention may be administered orally, sublingually, parenterally, subcutaneously, intramuscularly, intravenously, transdermally, topically or rectally.
- the active ingredient may be conventionally used.
- the pharmaceutically acceptable carriers are mixed together and administered to the animal or human in the form of an administration unit.
- Suitable administration unit forms include oral forms such as tablets, gel capsules, powders, granules and solutions or suspensions for oral administration, sublingual or buccal administration, parenteral, subcutaneous, intramuscular, intravenous, nasal Internal or intraocular administration forms and rectal administration forms.
- the main active ingredient is mixed with a pharmaceutically acceptable carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- a pharmaceutically acceptable carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- the tablets may be coated with sucrose or other suitable materials or treated in such a way that they have prolonged or delayed activity and continuously release a predetermined amount of active ingredient.
- a gel capsule preparation is obtained by mixing the active ingredient with a diluent and by pouring the obtained mixture into a soft or hard capsule.
- Formulations in the form of syrups or elixirs may contain the active ingredient along with sweetening agents, preservatives, and perfuses, and suitable colorants.
- the powder or granules which may be dispersed in water may contain the active ingredient in admixture with a dispersing agent, a surfactant, a wetting or suspending agent, and a flavoring or sweetening agent.
- the pharmaceutical composition contains polyoxyethylene castor oil and its derivatives, dimethyl sulfoxide, ethanol, glycerin, N, N-dimethylformamide, polyethylene glycol 300-3000, cyclodextrin, glucose, Tween One or more of polyethylene glycol monostearate.
- Suppositories are used for rectal administration, which are prepared using a binder that melts at the rectal temperature, for example, cocoa butter or polyethylene glycol.
- An aqueous suspension, an isotonic physiological saline solution or a sterile and injectable solution comprising a pharmacologically compatible dispersant and/or wetting agent for parenteral, intranasal or intraocular administration Apply.
- the pharmaceutical composition contains polyoxyethylene castor oil and its derivatives, dimethyl sulfoxide, ethanol, glycerin, N, N-dimethylformamide, polyethylene glycol 300-3000, cyclodextrin, glucose, Tween One of polyethylene glycol monostearate Or several.
- the active ingredient (possibly together with one or more additive carriers) can also be formulated as a microcapsule.
- the compounds of the invention can be administered at doses between 0.01 mg/day and 5000 mg/day, in a single dose/day manner or in several doses throughout the day, for example, the same dose twice daily. .
- the daily dose administered is advantageously between 0.1 mg and 200 mg, even more advantageously between 2.5 mg and 50 mg. It may be desirable to use dosages outside of these ranges, as will be appreciated by those skilled in the art.
- the pharmaceutical composition may also be formulated for external administration. It can be introduced into the usual form of the application type (i.e., especially lotions, foams, gels, dispersants, sprays), the usual forms having excipients, in particular excipients It is able to penetrate the skin in order to improve the properties and accessibility of the active ingredients.
- these compositions generally further comprise a physiologically acceptable medium, which usually comprises water or a solvent, for example an alcohol, an ether or an ethylene glycol.
- the composition may further comprise a surfactant, a preservative, a stabilizer, an emulsifier, a thickener, other active ingredients that produce a complementary effect or a possible synergistic effect, trace elements, essential oils, perfumes, colorants, collagen, Chemical or mineral filter.
- pharmaceutically acceptable is understood to mean that it is used in the preparation of a pharmaceutical composition which is generally safe, non-toxic, biologically or otherwise satisfying needs and said combination Objects can be accepted for use in mammals and humans.
- a "pharmaceutically acceptable salt” of a compound is understood to mean a salt which is a pharmaceutically acceptable (as defined herein) salt and which possesses the desired pharmacological activity of the parent compound.
- This salt includes:
- Acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc., or with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid , fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, sticky
- a metal ion such as an alkali metal ion (for example, Na + , K + or Li + ), an alkaline earth metal ion (such as Ca 2+ or Mg 2+ ) or aluminum ion.
- a salt formed when coordinated with an organic or inorganic base include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like.
- Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydroxide.
- “Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers. And excipients.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
- Ts is p-toluenesulfonate.
- the experimental methods in the examples of the present invention which do not specify the specific conditions are usually in accordance with conventional conditions or according to the conditions recommended by the raw material or the manufacturer of the commodity. Reagents without specific source are routine reagents purchased from the market.
- the compound of the formula (IV) is synthesized by a reference method ( Jiang, X.-J. et . al , Chem . Eur . J. 2016 , 22 , 8273-8281 ).
- Nuclear Magnetic Resonance Instrument Bruker ARX-400 high resolution high resolution nuclear magnetic resonance instrument.
- Mass Spectrometry QSTAR Elite tandem quadrupole time-of-flight mass spectrometer.
- PBS buffer phosphate buffer
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
- NMR chemical shift ( ⁇ ) is given in units of 10 -6 (ppm).
- the solvent was determined to be deuterated chloroform (CD 3 Cl) and the internal standard was tetramethylsilane (TMS).
- TMS tetramethylsilane
- s is a single peak
- bs is a broad single peak
- d is a doublet
- t is a triplet
- qdt is a quartet
- m is a multiple or a large number of peaks
- dd is a doublet.
- the thin layer chromatography silica gel plate uses Qingdao GF254 silica gel plate, and the silica gel plate used for thin layer chromatography (TLC) has a specification of 0.15 mm to 0.2 mm, and the thin layer chromatography separation and purification product adopts a specification of 0.4 mm to 0.5 mm.
- the solution in the reaction means an aqueous solution unless otherwise specified.
- the temperature of the reaction was room temperature unless otherwise specified.
- step 1
- Test case in vitro anti-tumor cell light-sensitive experiment
- Test article Compound 2 of the present invention
- hematoporphyrin injection (English name: Hematoporphyrin Injection; trade name: Xibo, produced by Chongqing Huading Modern Biopharmaceutical Co., Ltd.).
- Test cells human breast cancer cells MCF-7
- RPMI-1640 complete medium Add 500,000 U of penicillin/streptomycin, 56 mL of fetal bovine serum to 500 mL of RPMI-1640 liquid medium (GIBCO), and mix.
- MTT solution MTT: 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide, purchased from MP Company, USA
- concentration is dissolved in PBS solution, sterilized by filtration, and is now ready for use.
- test sample is formulated into a mother liquor having a concentration of 1 mM in DMSO; 100 ⁇ L of a 1 mg/mL mother liquor is taken during the experiment, and 1.15 mL of 0.5% (w/w) polyoxyethylene castor oil pH 7.4 PBS is added.
- pH 6.5 PBS buffer formulated into 80 ⁇ g / mL drug solution, and diluted with the corresponding PBS buffer into different concentrations of the drug solution, the pH value of the drug solution is kept unchanged during the dilution process, and the drug solution is cultured immediately after preparation. .
- the final concentration of DMSO in each drug and negative control group was ⁇ 1%.
- Xibofen is a 25 mL preparation containing 5 mg of liquid solution at a concentration of 5 mg/mL. Take 100 ⁇ L of 5 mg/mL preparation, add 4.90 mL of pH 7.4 PBS or pH 6.5 PBS buffer, and dilute to different concentrations of the solution with the corresponding PBS buffer. Keep the pH of the solution unchanged during the dilution process. Cell dosing culture is performed immediately.
- the culture was continued at 37 ° C and 5% CO 2 . hour. After 24 hours, add 5 mg/mL MTT per well, 20 ⁇ L, and incubate for 4 hours at 37 ° C, 5% CO 2 , carefully aspirate the supernatant, add 200 ⁇ L of DMSO to each well, and shake for 10 minutes to form the formed formazan. After the particles were sufficiently dissolved, the absorbance was measured by a microplate reader, and the measurement wavelength was 570 nm, and the reference wavelength was 630 nm.
- the light source is connected to the insulated water tank by a 200W halogen lamp and a filter larger than 610 nm, and the light dose is 48 J cm -2 .
- tumor cell growth inhibition rate (%) [(negative control group OD mean - administration group OD mean) / negative control group OD mean value] ⁇ 100%.
- the calculation of the half-inhibitory concentration IC 50 was determined by logit regression.
- the experimental results showed that all the tested compounds showed no cytotoxicity at concentrations up to 5000 ng/mL in the dark, but the human breast cancer cells MCF-7 at pH 6.5 and pH 7.4 under illumination.
- the lethal concentration IC 50 value or less between 3800-4100ng / mL.
- the concentration was as high as 8000 ng/mL, and there was no photosensitivity at the time of illumination, but Compound 2 exhibited very high photosensitivity when cultured at pH 6.5, IC 50 The value is 125 ng/mL, showing a very significant tumor microcellular environment targeting.
- Solid tumors have a slightly acidic environment, such as lung cancer, stomach cancer, esophageal cancer, breast cancer, bladder cancer, prostate cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, colon cancer, skin cancer, head and neck.
- Solid tumors such as cancer, ocular tumor, uterine cancer and ovarian cancer all have a slightly acidic environment, and the compound disclosed in the present patent or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same can be prepared as a photosensitizing drug for treating the above cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及pH敏感的缩酮连接的胆固醇-氟硼二吡咯衍生物及其制备方法和在医药上的应用。特别地,涉及通式(I)所示的胆固醇-氟硼二吡咯衍生物、其制备方法及含有该配合物的药物组合物,以及其作为光敏剂的用途,特别是在治疗癌症中的用途,其中通式(I)中的各取代基与说明书中的定义相同。由于胆固醇基团的存在,该系列配合物很难被肿瘤细胞和正常细胞摄取,但在肿瘤组织细胞外微酸环境下,缩酮键发生水解反应,氟硼二吡咯的水解衍生物能很容易被癌细胞摄取,并展现极高的光敏活性,它们可制备成肿瘤细胞外微酸环境靶向光敏药物。
Description
本发明属于医药领域,涉及氟硼二吡咯衍生物及其制备方法及其在医药上的应用,本发明公开了其作为光敏剂,用于治疗癌症的用途。
光动力治疗(Photodynamic Therapy,简称PDT),又称光辐射疗法(Photoradiation Therapy,简称PRT)或称光化学疗法(Photochemotherapy),是一种基于特定化学物质的光化学反应原理的治疗方法。所用的化学物质称为肿瘤化学诊治药物(也称光敏剂,Photosensitizer,简称PS)。PDT疗法过程是通过静脉注射将光敏剂注入体内(对于皮肤也可以将其涂于患处),经过一定时间后用特定波长的光照射肿瘤组织,富集在肿瘤组织的光敏剂在光的激发下,产生一系列光物理化学反应,产生细胞毒性的活性氧,从而杀死癌细胞破坏肿瘤组织。
1996年被美国FDA批准用于临床,1997年FDA将其列入肿瘤治疗的五类基本方法(手术、放疗、化疗、光动力、生化免疫)之一。和传统的疗法相比,PDT疗法具有创伤很小、毒性低微、选择性好、适用性好、可重复治疗、可姑息治疗、可协同手术提高疗效、可消灭隐性癌病灶、可保护容貌及重要器官功能、治疗时间短等优势。
光动力疗法还可以有效地治疗细菌感染、口腔感染、黄斑变性眼病、动脉硬化、创伤感染以及皮肤病等非癌症疾病。光敏剂还可以用于光动力消毒,最主要的是用于血液和血液衍生物的灭菌消毒。同时,利用光敏剂的荧光性质进行光动力诊断,也是医用光敏剂的一个重要用途。
光动力治疗的关键在于光敏剂,光动力疗效取决于光敏剂的优劣。基于光动力治疗在治疗肿瘤和其他疾病方面的潜力,科学界普遍认为,光动力治疗将成为21世纪的重要医疗方法。现在临床主要应用的光敏剂为卟非姆纳(Porfimer sodium,Photofin),该药先后在荷兰、加拿大、日本、美国、法国、德国、英国等28个国家和地区上市。我国在光动力治疗(PDT)方面的研究较美国、日本等国起步较迟,但进步较快。20世纪80年代初至今,为发展光动力治疗做了大量工作,与国外报道的成果相比,其深度和广度并无太大差距。重庆华鼎现代生物制药有限责任公司研制、生产用以治疗肿瘤的血卟啉(Hematoporphyrin,喜泊分),已经由国家食品药品管理局(SFDA)正式批准生产、销售并应用于临床。喜泊分是我国唯一上市的抗癌光敏剂,是国外上市的卟非姆纳类似物,均是血卟啉衍生物,同属于第一代抗癌光敏药物。
尽管卟非姆纳和喜泊分在临床上取得了成功,但其组分复杂,各种成分在光动力损伤中的作用至今也未弄清,占药物总量20%以上的非活性成分不仅不能对病变的靶组织产生有效的光动力损伤作用,反而成为导致正常组织发生光敏反应的祸首。另外第一代光敏药物对肿瘤的靶向作用不强,研究高效、低毒的具有肿瘤靶向性的光敏药物是最近的研究热点。
肿瘤实体组织部位存在的缺氧微环境导致该部位肿瘤细胞外的pH值较低(在6.5左右),而正常组织细胞外pH值为7.4左右。肿瘤实体组织和正常组织之间的pH值差异为肿瘤靶向药物的设计提供了新的策略。本专利发明人近年报道了多个系列的pH敏感的光敏药物,比如轴向氨基衍生物取代硅酞菁,通过氨基在不同pH环境下的离子化程度不同影响光敏活性(Jiang,X.-J.et.al,Chem.Commun.,2010,46,3188-3190);轴向苯基衍生物取代硅酞菁,通过pH环境下酞菁分子的聚集程度不同影响光敏活性(Jiang,X.-J.et.al,Chem.Eur.J.,2010,16,4777-4783);通过pH敏感的缩酮键连接的氟硼二吡咯衍生物和二茂铁衍生物,由于二茂铁为荧光淬灭剂,可以通过光诱导电子转移(photoinduced electron transfer,PET)过程淬灭氟硼二吡咯衍生物的光敏活性,但在微酸环境下,缩酮键断裂,二吡咯衍生物的光敏活性得到恢复(Jiang,X.-J.et.al,Chem.Eur.J.2016,22,8273-8281)。但这些化合物和目前报道的大多数pH敏感的药物均不是肿瘤细胞外微酸环境靶向药物,这是由于肿瘤细胞和正常细胞的亚细胞组织如线粒体、溶酶体等均显酸性,溶酶体的pH值更可以低至5。这些化合物在被肿瘤细胞和正常细胞摄取后,可以被亚细胞组织中的酸激发光敏活性,损伤肿瘤细胞和正常细胞。
发明内容
本发明公开了一系列肿瘤细胞外微酸环境靶向光敏药物。公开了一系列缩酮连接的胆固醇-氟硼二吡咯衍生物的结构、合成及应用。在氟硼二吡咯衍生物引入胆固醇基团,氟硼二吡咯衍生物和胆固醇之间用酸敏感的缩酮键连接,由于胆固醇的非极性特性和大位阻作用,胆固醇-氟硼二吡咯衍生物很难被癌细胞和正常细胞摄取,但在肿瘤实体组织癌细胞外的微酸环境下,缩酮键发生水解反应,胆固醇基团脱落,氟硼二吡咯水解衍生物能被癌细胞摄取并展现极高的光敏活性,它们是肿瘤细胞外微酸环境靶向光敏药物。
本发明提供的一种通式(I)所示的化合物:
或其药学上可接受的盐。
通式(I)所示的化合物在微酸环境下的水解反应化学式(1)
通式(I)的所示化合物的水解产物为通式(V)化合物的结构与已有文献报道的化合物结构相同和类似(Jiang,X.-J.et.al,Chem.Eur.J.2016,22,8273-8281),这些化合物在肿瘤细胞摄取率高,在很低的浓度下展现非常高的光敏活性。
本发明还提供一种制备通式(I)所示的化合物的方法,该方法包括:
第1步,所述溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、三氯甲烷和四氢呋喃;所述反应在-5~80℃温度下进行;所述碱性条件由选自吡啶、三乙胺、氢化钠和4-N,N-二甲基吡啶等试剂提供;所述通式(II)化合物与胆固醇甲酰氯的摩尔比为1∶0.2~2;
第2步,所述溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、三氯甲烷和四氢呋喃;所述的催化剂选用三乙胺、吡啶、N,N-二甲基吡啶;所述缩合剂选用二环己基碳二亚胺、二异丙基碳二亚胺、1-(3-二甲胺基丙基)-3-乙基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐、O-(7-氮杂苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓四氟硼酸盐、O-(N-丁二酰亚胺基)-二(二甲胺基)碳鎓四氟硼酸盐中的至少一种;和/或所述缩合活化剂选用1-羟基苯并三氮唑、1-羟基-7-偶氮苯并三氮唑、N-羟基琥珀酰亚胺、N-羟基邻苯二甲酰亚胺中的一种;所述反应在-5~80℃温度下进行;所述通式(IV)化合物与通式(III)化合物的摩尔比为1∶0.4~4;通式(IV)化合物与缩合剂的摩尔比为1∶0.4~4。
如果有必要,通过本领域技术人员熟知的方法,如通过蒸馏、通过硅胶柱色谱法或者通过高效液相色谱法(HPLC)也可以纯化化合物。
本发明还提供一种药物组合物,其含有治疗有效量的通式(I)所示的化合物或或其药学上可接受的盐,以及药学上可接受的载体、稀释剂或赋形剂。
本发明还涉及通式(I)所示的化合物或其药学上可接受的盐,或包含其的药物组合物在制备光动力药物或光敏药物中的用途。
本发明还涉及通式(I)所示的化合物或其药学上可接受的盐,或包含其的药物组合物在制备治疗癌症的药物中的用途。其中所述的癌症选自其中所述的癌症选自肺癌、胃癌、食管癌、乳腺癌、膀胱癌、前列腺癌、胰腺癌、胆管癌、直肠癌、结肠癌、皮肤癌、头颈部癌症、眼肿瘤、子宫癌和卵巢癌,优乳腺癌。
本发明还涉及通式(I)所示的化合物或其药学上可接受的盐,或包含其的药物组合物,其用作光动力药物或光敏药物。
本发明还涉及通式(I)所示的化合物或其药学上可接受的盐,或包含其的药物组合物,其用于治疗癌症。其中所述的癌症选自肺癌、胃癌、食管癌、乳腺癌、膀胱癌、前列腺癌、胰腺癌、胆管癌、直肠癌、结肠癌、皮肤癌、头颈部癌症、眼肿瘤、子宫癌和卵巢癌,优选乳腺癌。
本发明还涉及一种治疗癌症的方法,其包括给予所需患者治疗有效量的通式(I)所示的化合物或其药学上可接受的盐,或包含其的药物组合物,然后用适宜的光源照射。所述适宜的光源可以由普通光源连接合适的滤光片来提供或由特定波长的激光来提供,光源的波长范围为550~900nm,优选620~720nm。
根据本发明的化合物可以被口服施用、舌下施用、肠胃外施用、皮下施用、肌内施用、静脉内施用、经皮施用、局部施用或直肠施用。
在本发明的药用化合物中,对于口服施用、舌下施用、肠胃外施用、皮下施用、肌内施用、静脉内施用、经皮施用、局部施用或直肠施用而言,活性成分可以与常规的药用载体混合在一起,以施用单位的形式施用于动物或人类。适合的施用单位形式包含口服形式如片剂、凝胶胶囊剂、粉剂、颗粒剂和口服的溶液剂或混悬剂,舌下或口腔施用形式,肠胃外、皮下、肌内、静脉内、鼻内或眼内施用形式和直肠施用形式。
当固体组合物被制备成片剂形式时,主要活性成分与药用载体如明胶、淀粉、乳糖、硬脂酸镁、滑石、阿拉伯胶等混合。片剂可以采用蔗糖或其他适合的材料包衣或者以如此的方式处理以至于其具有延长的或延迟的活性并且连续释放预定量的活性成分。
通过将活性成分与稀释剂混合并通过将获得的混合物倾倒入软质或硬质胶囊中来获得凝胶胶囊制剂。
糖浆剂或酊剂形式的制剂可以包含活性成分连同甜味剂、防腐剂以及芳香剂和适当的着色剂。
可分散于水中的粉剂或颗粒剂可以包含活性成分,其与分散剂、表面活性剂、润湿剂或悬浮剂以及与矫味剂或甜味剂混合在一起。其药物组合中含有聚氧乙烯蓖麻油及其衍生物、二甲亚砜、乙醇、甘油、N,N-二甲基甲酰胺、聚乙二醇300-3000、环糊精、葡萄糖、吐温、聚乙二醇单硬脂酸酯中的一种或几种。
栓剂用于直肠施用,其采用在直肠温度下熔化的粘合剂,例如,可可脂或聚乙二醇来制备。
水性混悬剂、等渗的生理盐水溶液剂或无菌的且可注射的溶液剂(其包含药理学上可兼容的分散剂和/或润湿剂)用于肠胃外、鼻内或眼内施用。其药物组合中含有聚氧乙烯蓖麻油及其衍生物、二甲亚砜、乙醇、甘油、N,N-二甲基甲酰胺、聚乙二醇300-3000、环糊精、葡萄糖、吐温、聚乙二醇单硬脂酸酯中的一种
或几种。
活性成分(可能与一种或多种添加剂载体一起)也可以被配制成微囊剂。
本发明的化合物能够以介于0.01mg/天和5000mg/天之间的剂量来使用,以单一剂量/天的方式来提供或者以全天内若干剂量的方式来施用,例如,相同剂量每天两次。所施用的日剂量有利地介于0.1mg和200mg之间,甚至更有利地介于2.5mg和50mg之间。使用超出这些范围的剂量可能是需要的,本领域技术人员自身将会意识到这一点。
在本发明的一个特定实施方案中,药物组合物也可以被配制用于外部施用。它可以被引入到该施用类型的常用形式(即,特别是洗剂、泡沫剂、凝胶剂、分散剂、喷雾剂)中,所述常用形式具有赋形剂,所述赋形剂特别地能够穿透皮肤,以便于改善活性成分的性质和可接近性。除了根据本发明的组合物之外,这些组合物通常进一步包含生理上可接受的介质,所述介质通常包含水或溶剂,例如,醇、醚或乙二醇。所述组合物还可以包含表面活性剂、防腐剂、稳定剂、乳化剂、增稠剂、产生互补效果或可能的协同效果的其他活性成分、微量元素、精油、香料、着色剂、胶原蛋白、化学或矿物过滤剂。
定义
除非有相反陈述,否则下列用在说明书和权利要求书中的术语具有下述含义。
在本发明中,“药学上可接受的”被理解为是指其用于制备药物组合物,所述组合物一般是安全的,无毒的,在生物学或其他方面满足需要并且所述组合物可以被接受用于兽类和人类药物用途。
在本发明中,化合物的“药学上可接受的盐”被理解为指代下列盐,其是药学上可接受的(如本文所定义的)盐并且其具备预期的母体化合物的药理活性。这种盐包括:
(1)与无机酸如盐酸、氢溴酸、硫酸、硝酸、磷酸等形成的酸加成盐,或与有机酸如乙酸、苯磺酸、苯甲酸、樟脑磺酸、柠檬酸、乙磺酸、富马酸、葡庚糖酸、葡糖酸、谷氨酸、乙醇酸、羟萘酸、2-羟基乙磺酸、乳酸、马来酸、苹果酸、扁桃酸、甲磺酸、粘康酸、2-萘磺酸、丙酸、水杨酸、琥珀酸、二苯甲酰基-L-酒石酸、酒石酸、对甲苯磺酸、三甲基乙酸、三氟乙酸等形成的酸加成盐;和
(2)当母体化合物中存在的酸质子被金属离子,例如,碱金属离子(例如,Na+、K+或Li+),碱土金属离子(如Ca2+或Mg2+)或铝离子代替;或者与有机碱或无机碱配位时形成的盐。可接受的有机碱包括二乙醇胺、乙醇胺、N-甲基葡糖胺、三乙醇胺、氨丁三醇等。可接受的无机碱包括氢氧化铝、氢氧化钙、氢氧化钾、碳酸钠和氢氧化钠。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学/可药用的载体
和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
“Ts”为对甲基苯磺酸基。
通过阅读下列实施例,本领域技术人员将会更好地理解本发明。这些实施例仅用于解释本发明。
本发明实施例中未注明具体条件的实验方法,通常按照常规条件,或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂,为市场购买的常规试剂。式(IV)化合物参考文献方法合成得到(Jiang,X.-J.et.al,Chem.Eur.J.2016,22,8273-8281)。
核磁共振仪:Bruker ARX-400型高分辨高分辨核磁共振仪。
质谱:QSTAR Elite串联四级杆飞行时间质谱仪。
MTT检测仪器:Thermo Scientific Multiskan GO全波长酶标仪
PBS缓冲液:磷酸盐缓冲液
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR化学位移(δ)以10-6(ppm)的单位给出。测定溶剂为氘代三氯甲烷(CD3Cl),内标为四甲基硅烷(TMS)。使用下列缩写:s为单峰,bs为宽单峰,d为二重峰,t为三重峰,qdt为四重峰,m为多重峰或大量峰,dd为双二重峰等。
薄层层析硅胶板使用青岛GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
柱层析一般使用烟台黄海硅胶200~300目硅胶为载体。
实施例中如无特殊说明,反应均在氩气氛或氮气氛下进行。
实施例中如无特殊说明,反应中的溶液是指水溶液。
实施例中如无特殊说明,反应的温度为室温。
实施例中的反应进程的监测采用薄层色谱法(TLC)。
实施例1化合物1的合成
第1步;
在冰水浴中,把化合物1-1(1.62g,10mmol),氯甲酸胆固醇(2.2g,4.9mmol)和三乙胺(2g,20mmol)加入二氯甲烷(50mL),继续搅拌反应2小时,停止反应,向反应液中加入水(100mL),搅拌静置,收集有机相,有机相用无水硫酸钠干燥,减压蒸馏,粗产品用硅胶层析柱分离纯化,洗脱剂为三氯甲烷/甲醇(9∶1),得到白色固体1-2(1.53g,55%)。MS(ESI):m/z=598[M+Na]+。
第2步
将化合物式(IV)(1.06g,1.0mmol)和化合物1-2(1.15g,2mmol)溶解在N,N-二甲基甲酰胺(20mL),溶液温度降至0℃搅拌0.5小时,慢慢加入1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDC.HCL)(767mg,4mmol),4-N,N-二甲基吡啶(244mg,2mmol),反应液温度升到在60℃反应12小时。反应液冷却到室温,过滤,收率滤液,减压干燥去除溶剂,剩下固体用硅胶层析色谱分离纯化,解析剂为三氯甲烷/甲醇(9∶1v/v)收集主要组份,减压干燥得到绿色固体粉末1(0.45g,20%)。1H NMR(400MHz,CDCl3):δ8.11(d,J=16.4Hz,2H,CH=CH),7.60(d,J=8.4Hz,4H,ArH),7.56(d,J=16.4Hz,2H,CH=CH),7.13(d,J=8.4Hz,2H,ArH),7.06(d,J=8.4Hz,2H,ArH),6.97(d,J=8.4Hz,4H,ArH),5.51-5.55(m,4H,chol-6-CH),4.53(s,4H,CH2),4.35-4.39(m,4H,chol-6-CH),3.92(t,J=4.4Hz,2H,CH2),3.76-3.78(m,2H,CH2),3.70-3.74(m,2H,CH2),3.66-3.68(m,2H,CH2),3.55-3.59(m,2H,CH2),3.42-3.52(m,14H,CH2),3.20-3.35(s,7H,CH2,CH3),1.73-2.32(m,16H,chol),0.86-1.56(m,82H,chol,CH3),0.68(s,6H,chol-18-CH3)。MS(ESI):m/z=2177[M+H]+。
实施例2化合物2的合成
第1步
在冰水浴中,把化合物2-1(1.64g,10mmol),氯甲酸胆固醇(1.55g,3.5mmol)和吡啶(0.8g,10.1mmol)加入二氯甲烷(25mL),温度升到室温,继续搅拌反应2小时,停止反应,向反应液中加入水(100mL),搅拌静置,收集有机相,有机相用无水硫酸钠干燥,减压蒸馏,粗产品用硅胶层析柱分离纯化,洗脱剂为三氯甲烷/甲醇(15∶1),得到白色固体2-2(1.02g,49%)。MS(ESI):m/z=599[M+Na]+。
第2步
将化合物式(IV)(1.06g,1mmol)和化合物2-2(1.15g,2mmol)溶解在四氢呋喃(30mL),溶液温度降至0℃搅拌0.5小时,慢慢加入二环己基碳二亚胺(DCC)(412mg,2mmol),1-羟基苯并三唑(270mg,2mmol),三乙胺(404mg,4mmol),反应液温度升到在60℃反应12小时。反应液冷却到室温,过滤,收率滤液,减压干燥去除溶剂,剩下固体用硅胶层析色谱分离纯化,解析剂为三氯甲烷/甲醇(9∶1v/v)收集主要组份,减压干燥得到蓝色固体粉末2(0.29g,13%)。1H NMR(400MHz,CDCl3):δ8.10(d,J=16.4Hz,2H,CH=CH),7.61(d,J=8.4Hz,4H,ArH),7.58(d,J=16.4Hz,2H,CH=CH),7.15(d,J=8.4Hz,2H,ArH),7.05(d,J=8.4Hz,2H,ArH),6.96(d,J=8.4Hz,4H,ArH),5.32-5.35(m,2H,chol-6-CH),4.55(s,4H,CH2),4.35-4.40(m,2H,chol-3-CH),4.21-4.33(m,8H,CH2),3.93(t,J=4.4Hz,2H,CH2),3.77-3.79(m,2H,CH2),3.71-3.73(m,2H,CH2),3.67-3.69(m,2H,CH2),3.56-3.59(m,2H,CH2),3.40-3.53(m,10H,CH2),3.39(s,3H,CH3),1.70-2.29(m,16H,chol),0.88-1.58(m,82H,chol,CH3),0.68(s,6H,chol-18-CH3)。MS(ESI):m/z=2181[M+H]+。
测试例:体外抗肿瘤细胞光敏实验
供试品:本发明化合物2
阳性对照品:血卟啉注射液(英文名:Hematoporphyrin Injection;商品名:喜泊分,重庆市华鼎现代生物制药有限责任公司生产)。
测试细胞:人乳腺癌细胞MCF-7
主要试剂:1)RPMI-1640完全培养液:于500mL RPMI-1640液体培养液(GIBCO公司)中加入青霉素/链霉素10万U,胎牛血清56mL,混匀。2)MTT溶液(MTT:3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐,购于美国MP公司):将粉状MTT以5mg/mL的浓度溶于PBS溶液,过滤灭菌,现配现用。
实验方法:
1)供试品配制方法:将供试品用DMSO配成浓度为1mM的母液;实验时取100μL1mg/mL的母液,加入1.15mL 0.5%(w/w)聚氧乙烯蓖麻油pH 7.4PBS和pH 6.5PBS缓冲液,配制成80μg/mL药液,并用相对应的PBS缓冲液稀释成不同浓度的药液,稀释过程中保持药液pH值不变,药液配制后马上进行细胞加药培养。各药物和阴性对照组中DMSO的终浓度是≤1%。喜泊芬为5mL液体溶液含25mg制剂,浓度5mg/mL。取100μL 5mg/mL的制剂,加入4.90mLpH 7.4PBS或pH 6.5PBS缓冲液,并用相对应的PBS缓冲液稀释成不同浓度的药液,稀释过程中保持药液pH值不变,药液配制后马上进行细胞加药培养。
2)选用对数生长期的贴壁肿瘤细胞,用胰酶消化后,用含10%胎牛血清的RPMI 1640培养基配成适合浓度的细胞悬液,接种在96孔培养板中。每孔接种100μL,每加完一排将细胞悬液摇一下,加完细胞后轻轻水平转动培养板使细胞均匀地分散在皿孔表面,96孔板周围一圈孔加入无菌PBS,37℃,5%CO2培养24小时。然后分别加入不同浓度的受试药物、阳性药物、溶剂和培养液各100μL,每组3个平行孔。混匀后分为光照和避光两组,均在加药共培养2小时后,弃去培养基,重新加入不含供试品的培养基置37℃、5%CO2条件下继续培养24小时。24小时后,每孔加入5mg/mL MTT,20μL,37℃、5%CO2条件下孵育4小时后,仔细吸弃上清液,每孔加入200μL DMSO,振荡10分钟,使形成的甲臜颗粒充分溶解后,酶标仪检测吸光值,测定波长570nm,参考波长630nm。光源通过200W的卤素灯连接隔热水槽加大于610nm的滤光片提供,光剂量为48J cm-2。
3)药物对肿瘤细胞生长的抑制率的计算方法:肿瘤细胞生长抑制率(%)=[(阴性对照组OD均值-给药组OD均值)/阴性对照组OD均值]×100%。半数抑制浓度IC50的计算,采用logit回归法测定。
实验结果:
表1化合物2和喜泊分在照光时人乳腺癌细胞MCF-7的IC50(ng/mL)值
光敏药物 | 细胞pH 7.4药液培养 | 细胞pH 6.5药液培养 |
化合物2 | >8000 | 125 |
喜泊分 | 3800 | 4100 |
实验结果显示,在避光环境下,所有测试的化合物在浓度高达5000ng/mL时,没有显示细胞毒性,但在照光情况下喜泊分在pH 6.5和pH 7.4时对人乳腺癌细胞MCF-7的半致死浓度IC50值相差不大,在3800-4100ng/mL之间。但化合物2在pH 7.4的药液培养细胞时,浓度高达8000ng/mL,在照光时完全没有光敏活性,但化合物2在pH 6.5的药液进行培养细胞时,展现非常高的光敏活性,IC50值为125ng/mL,展现非常明显的肿瘤细胞外微酸环境靶向性。
目前已知,几乎所有的实体肿瘤都存在微酸环境,如肺癌、胃癌、食管癌、乳腺癌、膀胱癌、前列腺癌、胰腺癌、胆管癌、直肠癌、结肠癌、皮肤癌、头颈部癌症、眼肿瘤、子宫癌和卵巢癌等实体肿瘤均存在微酸环境,本专利公开的化合物或其药学上可接受的盐,或包含其的药物组合物均可以制备成光敏药物治疗上述癌症。
以上所述仅为本发明的实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (7)
- 根据权利要求2所述的方法,其中:第1步,所述溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、三氯甲烷和四氢呋喃;所述反应在-5~80℃温度下进行;所述碱性条件由选自吡啶、三乙胺、氢化钠和4-N,N-二甲基吡啶等试剂提供;所述通式(II)化合物与胆固醇甲酰氯的摩尔比为1:0.2~2;第2步,所述溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、三氯甲烷和四氢呋喃;所述的催化剂选用三乙胺、吡啶、N,N-二甲基吡啶;所述缩合剂选用二环己基碳二亚胺、二异丙基碳二亚胺、1-(3-二甲胺基丙基)-3-乙基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐、O-(7-氮杂苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓四氟硼酸盐、O-(N-丁二酰亚胺基)-二(二甲胺基)碳鎓四氟硼酸盐中的至少一种;和/或所述缩合活化剂选用1-羟基苯并三氮唑、1-羟基-7-偶氮苯并三氮唑、N-羟基琥珀酰亚胺、N-羟基邻苯二甲酰亚胺中的一种;所述反应在-5~80℃温度下进行;所述通式(IV)化合物与通式(III)化合物的摩尔比为1:0.4~4;通式(IV)化合物与缩合剂的摩尔比为1:0.4~4。
- 一种药物组合物,其含有治疗有效量的根据权利要求1中任意一项所述的通式(I)所示的化合物以及药学上可接受的载体、稀释剂或赋形剂。
- 根据权利要求1中任意一项所述的通式(I)所示的化合物或根据权利要求4所述的药物组合物在制备光动力药物或光敏药物中的用途。
- 根据权利要求1中任意一项所述的通式(I)所示的化合物或根据权利要求4所述的药物组合物在制备治疗癌症的药物中的用途。
- 根据权利要求6所述的用途,其中所述的癌症选自肺癌、胃癌、食管癌、乳腺癌、膀胱癌、前列腺癌、胰腺癌、胆管癌、直肠癌、结肠癌、皮肤癌、头颈部癌症、眼肿瘤、子宫癌和卵巢癌,优选乳腺癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610995708.4 | 2016-11-11 | ||
CN201610995708.4A CN106565760B (zh) | 2016-11-11 | 2016-11-11 | 氟硼二吡咯衍生物及其制备方法和在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018086243A1 true WO2018086243A1 (zh) | 2018-05-17 |
Family
ID=58542470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/070300 WO2018086243A1 (zh) | 2016-11-11 | 2017-01-05 | 氟硼二吡咯衍生物及其制备方法和在医药上的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106565760B (zh) |
WO (1) | WO2018086243A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107629063B (zh) * | 2017-09-25 | 2019-03-19 | 深圳市声光动力生物医药科技有限公司 | 酸敏感的酞菁锌-吉非替尼配合物及其制备方法和在医药上的应用 |
CN107629077B (zh) * | 2017-09-25 | 2019-03-19 | 深圳市声光动力生物医药科技有限公司 | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 |
WO2019056376A1 (zh) * | 2017-09-25 | 2019-03-28 | 深圳市声光动力生物医药科技有限公司 | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 |
CN108373478A (zh) * | 2017-12-13 | 2018-08-07 | 湖北远大生命科学与技术有限责任公司 | 一类牛磺酸取代的氟硼荧荧光化合物及其制备方法和用途 |
KR102009601B1 (ko) * | 2018-04-30 | 2019-08-09 | 고려대학교 산학협력단 | 종양 표적화 광역학 치료제 |
WO2021169661A1 (zh) * | 2020-02-28 | 2021-09-02 | 复旦大学 | 4位阳离子双取代bodipy类化合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103183697A (zh) * | 2013-02-26 | 2013-07-03 | 南京大学 | 基于二联杂环并吡咯基团的近红外氟硼二吡咯化合物及其制法和用途 |
CN103755753A (zh) * | 2014-01-25 | 2014-04-30 | 福州大学 | 一类糖基化氟硼二吡咯衍生物及其制备和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104387412B (zh) * | 2014-12-17 | 2016-01-06 | 福州大学 | 埃罗替尼修饰的氟硼二吡咯衍生物及其制备和应用 |
CN105833271B (zh) * | 2016-04-14 | 2019-02-15 | 江苏师范大学 | 一种金刚烷修饰的近红外氟硼二吡咯光敏剂及其制备方法 |
-
2016
- 2016-11-11 CN CN201610995708.4A patent/CN106565760B/zh active Active
-
2017
- 2017-01-05 WO PCT/CN2017/070300 patent/WO2018086243A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103183697A (zh) * | 2013-02-26 | 2013-07-03 | 南京大学 | 基于二联杂环并吡咯基团的近红外氟硼二吡咯化合物及其制法和用途 |
CN103755753A (zh) * | 2014-01-25 | 2014-04-30 | 福州大学 | 一类糖基化氟硼二吡咯衍生物及其制备和应用 |
Non-Patent Citations (1)
Title |
---|
JIANG, XIONGJIE ET AL.: "pH-and Thiol-Responsive BODIPY-Based Photosensitizers for Targeted Photodynamic Therapy", CHEM. EUR. J., vol. 22, no. 24, 3 May 2016 (2016-05-03), pages 8273 - 8281, XP055474100, ISSN: 0947-6539 * |
Also Published As
Publication number | Publication date |
---|---|
CN106565760A (zh) | 2017-04-19 |
CN106565760B (zh) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018086243A1 (zh) | 氟硼二吡咯衍生物及其制备方法和在医药上的应用 | |
EP3111940B1 (en) | Silicon phthalocyanine complex, preparation method and medicinal application thereof | |
CN107629077B (zh) | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 | |
WO2018086241A1 (zh) | pH敏感的1,4-二取代酞菁锌配合物及其制备方法和在医药上的应用 | |
WO2018086242A1 (zh) | pH敏感的轴向取代硅酞菁配合物及其制备方法和在医药上的应用 | |
KR20190070925A (ko) | 신규 클로린 e6 유도체 및 이의 약학적으로 허용가능한 염, 이의 제조방법 및 응용 | |
CN114736214B (zh) | 一种倍半萜衍生物、其药物组合物及其制备方法和用途 | |
CN113845551B (zh) | 一种具有光动力抗三阴乳腺癌活性的Pt(Ⅱ)配合物及其制备方法和应用 | |
CN114555607B (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
CN114478561B (zh) | 一种依帕司他石蒜碱偶联物及其制备方法和用途 | |
WO2019056376A1 (zh) | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 | |
WO2019056375A1 (zh) | 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用 | |
CN114656453A (zh) | 七甲川吲哚花菁-tempo化学偶链小分子和制备方法及其制备辐射防护制剂的应用 | |
CN110981865B (zh) | 一种用于治疗脑胶质瘤的药物及其制备方法 | |
CN108640965B (zh) | 2-取代-18β-甘草次酸衍生物及其应用 | |
CN107629063B (zh) | 酸敏感的酞菁锌-吉非替尼配合物及其制备方法和在医药上的应用 | |
WO2019056374A1 (zh) | 酸敏感的硼亚酞菁-吉非替尼配合物及其制备方法和在医药上的应用 | |
CN110183471B (zh) | 一种哌嗪类衍生物及制备方法及应用 | |
US5567707A (en) | Acronycine analogues | |
WO2019056373A1 (zh) | 酸敏感的酞菁锌-吉非替尼配合物及其制备方法和在医药上的应用 | |
CN107556335B (zh) | 酸敏感的硼亚酞菁-吉非替尼配合物及其制备方法和在医药上的应用 | |
CN107474065B (zh) | 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用 | |
CN116284145A (zh) | 一种光释放钌配合物制备及其抗耐药肿瘤的应用 | |
CN118161510A (zh) | 醉茄素a类化合物的应用 | |
WO2024114953A1 (en) | Phyllochlorin analogues suitable for use in photodynamic therapy (pdt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17869462 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17869462 Country of ref document: EP Kind code of ref document: A1 |